trametinib + pemetrexed + carboplatin

This is a combination regimen consisting of **trametinib** (a reversible, highly selective inhibitor of MEK1 and MEK2, components of the mitogen-activated protein kinase pathway), **pemetrexed** (a folate antimetabolite that inhibits several enzymes involved in purine and pyrimidine synthesis, leading to antineoplastic effects), and **carboplatin** (a platinum-based chemotherapy agent that crosslinks DNA and triggers apoptosis in rapidly dividing cells). The combination is not an approved or widely established named therapy, but is under investigation or considered for synergistic antitumor activity, particularly for advanced non-small cell lung cancer (NSCLC), especially where BRAF pathway inhibition may be beneficial[5][3][2]. Primary indication for such combinations (with or without trametinib) is **non-squamous NSCLC** and occasionally mesothelioma[3][6][8]. Trametinib is primarily approved in combination with dabrafenib for BRAF V600E/K mutation-positive cancers[5].

Other names

trametinibpemetrexedcarboplatin